Tovecimig
Based on 1 Customer Validation
Tovecimig (CTX-009) is a bispecific antibody targeting DLL4 and VEGF-A. Tovecimig contains two single-chain variable fragments (scFv) that bind human DLL4, and these fragments are linked to the C-terminus of the heavy chain that binds human VEGF-A. Tovecimig blocks the DLL4/NOTCH1 and VEGF signaling pathways, inhibiting DLL4-mediated Notch signaling and VEGF-A-mediated angiogenic signaling in tumor angiogenesis. Tovecimig can be used in research on refractory metastatic colorectal cancer, advanced biliary tract cancer, solid tumors, gastric cancer, and colon cancer.
For research use only. We do not sell to patients.
- Purity : 97.39%
- CAS No.: 2923284-73-3
- Molecular Weight:199.624 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
All VEGFR Isoforms
More
Biological Activity
Description
Isotype
IgG1-kappa-[scFv]2-lambda-heavy
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
VEGFA & DLL4
In Vitro
In Vivo
Tovecimig is active in the CT26 model and combines with mCTX-471 for enhanced tumor growth control[4].
Tovecimig is active as a single agent in the 4T1 isograft model[4].
Tovecimig (ABL001) (6.5 mg/kg; i.p.; twice per week) monotherapy inhibits tumor progression in the GAPF006 gastric cancer xenograft model[5].
Tovecimig (3.25 mg/kg; i.p.; twice per week) combined with Paclitaxel (HY-B0015) more potently inhibits tumor progression than Tovecimig alone in the GAPF006 gastric cancer xenograft model[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nu/nu (female, 8 weeks old) injected with GAPF006 cells[5]
-
Dosage:6.5 mg/kg
-
Administration:i.p.; twice per week
-
Result:Monotherapy produced 53.3% tumor growth inhibition in the GAPF006 gastric cancer xenograft model.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa-[scFv]2-lambda-heavy
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized VEGF121 Protein, Human (120 a.a, HY-P7420) can bind Tovecimig. The EC50 for this effect is 10.9 ng/mL. -
Immobilized Delta-like protein 4/DLL4 Protein, Human (HEK293, HY-P72972) can bind Tovecimig. The EC50 for this effect is 16.06 ng/mL. -
Flow cytometric analysis of 1X106 HeLa cells with Tovecimig (HY-P991033, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2923284-73-3
-
Appearance Liquid
-
Molecular Weight 199.624 kDa
-
Color Colorless to light yellow
-
SMILES
[Tovecimig]
-
Synonyms
CTX-009; ES 104
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)